Atara Biotherapeutics
-
Atara Approval Marks Cell Therapy First; Entrada on Hold, Bluebird Freed & More
The first regulatory approval of an allogeneic cell therapy goes to Atara Biotherapeutics. Other regulatory news highlights from the past week include proposed reforms of the FDA’s accelerated approval process, approval of the first gene therapy for bladder cancer, and a clinical hold for a biotech developing a new class of medicines.
-
In CAR-Ts for solid tumors, is off-the-shelf the way to go?
At the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day in New York Thursday, industry insiders gathered to talk about CAR-Ts in solid tumor cancers.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Atara’s EBV-CTLs show responses in hard-to-treat transplant complication
The company’s adoptive cell therapy produced responses in central nervous system PTLD, a frequently lethal complication of stem cell and solid organ transplants.